Is KAMADA LTD (KMDA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 2.2% / 30% | 15.3% / 30% | 4.5% / 30% | 1.32% / 5% | ✓ HALAL |
| DJIM | 2.2% / 33% | 15.3% / 33% | 4.5% / 33% | 1.32% / 5% | ✓ HALAL |
| MSCI | 3.0% / 33% | 21.1% / 33% | 6.2% / 33% | 1.32% / 5% | ✓ HALAL |
| S&P | 2.2% / 33% | 15.3% / 33% | 4.5% / 33% | 1.32% / 5% | ✓ HALAL |
| FTSE | 3.0% / 33% | 21.1% / 33% | 6.2% / 50% | 1.32% / 5% | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 42.3% | |
| Operating Margin | 7.9% | |
| Net Margin | 11.2% | |
| Return on Equity (ROE) | 7.6% | |
| Return on Assets (ROA) | 4.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $25M |
| Free Cash Flow | $16M |
| Total Debt | $12M |
| Debt-to-Equity | 4.3 |
| Current Ratio | 4.1 |
| Total Assets | $379M |
Price & Trading
| Last Close | $8.22 |
| 50-Day MA | $8.55 |
| 200-Day MA | $7.51 |
| Avg Volume | 75K |
| Beta | 0.3 |
|
52-Week Range
$5.54
| |
About KAMADA LTD (KMDA)
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
Purification Calculator
As a halal stock with 1.32% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is KAMADA LTD (KMDA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), KAMADA LTD is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is KAMADA LTD's debt ratio?
KAMADA LTD's debt ratio is 2.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 3.0%.
Does KAMADA LTD require dividend purification?
Yes, KAMADA LTD has an impermissible income ratio of 1.32%, which means 1.32% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are KAMADA LTD's key financial metrics?
KAMADA LTD has a market capitalization of $471M, trailing P/E ratio of 23.3, and revenue of $180M. The company maintains a gross margin of 42.3% and a net margin of 11.2%. Return on equity stands at 7.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.